Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

London pre-open: Stocks to edge up; central bank announcements eyed

(Sharecast News) - London stocks were set to edge up at the open on Monday as investors eyed a week packed with central bank policy announcements. The FTSE 100 was called to open around 11 points higher.

Ipek Ozkardeskaya, senior analyst at Swissquote Bank, said: "The European Central Bank (ECB), the Bank of Canada (BoC), the Reserve Bank of Australia (RBA) and the Swiss National Bank (SNB) will announce their latest policy verdict throughout this week and all - except the RBA - are expected to lower their rates.

"The BoC is expected to cut by 50bp while the SNB and the ECB are expected to announce a 25bp cut. Some investors are convinced that the ECB could announce more than a 25bp cut. Either it could go bigger with a 50bp cut, or cut by 25bp but shift their focus from inflation to economic growth. I believe that the second option is more plausible. If that's the case, we should not see a significant selloff in the euro post-decision."

Earlier, data from the National Bureau of Statistics showed that consumer price inflation in China fell to a five-month low in November, slowing to 0.2% year-on-year from 0.3% the month before and falling short of expectations of 0.5%.

Core inflation - which excludes food and fuel prices - rose 0.3% in November, down from 0.2% in October.

In UK corporate news, GSK said the US Food and Drug Administration has agreed to look at data from its MATINEE study to support the regulatory review process to obtain a new indication for the use of its Nucala drug as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease.

The study met its primary endpoint with the addition of mepolizumab to inhaled maintenance therapy, achieving a "statistically significant and clinically meaningful reduction" in the annualised rate of moderate/severe exacerbations versus placebo with patients treated for 52-104 weeks.

Early-stage science investor IP Group said it plans to increase its share buyback plan after raising £15m from the sale of minority holdings in several portfolio companies.

The company said it has agreed the sale of stakes of less than 10% each in nine portfolio companies across its balance sheet and managed funds to Lexham Partners.

All proceeds will go towards its share repurchase programme, which will rise to £45m, up from the £30m previously planned.

Share this article

Related Sharecast Articles

Europe midday: Shares pare losses as investors digest China tariff move
(Sharecast News) - European stocks pared losses as investors digested China's retaliatory moves against US tariffs and the 30-day pause on levies against Canada and Mexico.
US pre-open: Futures slightly lower as tariff headlines remain in focus
(Sharecast News) - Wall Street futures were in the red ahead of the bell on Tuesday as the effects of the new White House administration's tariffs on a number of its closest trading partners continued to be seen.
Asia report: Markets bounce back from Trump tariff sell-off
(Sharecast News) - Asia-Pacific markets advanced on Tuesday as investor sentiment improved following Donald Trump's decision to pause tariffs on Mexico and Canada for a month.
London open: FTSE falls again as China retaliates against US
(Sharecast News) - London stocks were lower again in early trade on Tuesday following heavy losses a day earlier, after China announced retaliatory tariffs on a range of US imports.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.